Just a moment, the page is loading...

Metrics

Agreed Proposals

The table below provides details of approved Research Proposals that have signed Data Sharing Agreements.

Click here to download the Agreed Proposals Report.

Proposal number Sponsor/Funder Title Institution Lead researcher  
611 GSK Long-acting beta2-agonists for chronic obstructive pulmonary disease Cochrane Airways Group, at St George's University of London Kayleigh Kew Further Details
628 GSK Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada Arnoud J. Templeton, MD Further Details
631 GSK Predictors of BPH Progression Duke University Dr. Stephen Freedland, MD Further Details
637 GSK Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial New York University school of Medicine, NY, NY Sripal Bangalore Further Details
639 GSK Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease St Luke's-Roosevelt Hospital of the Columbia University of Physicians and Surgeons Saurav Chatterjee MD Further Details
645 GSK The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension New York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NY Partha Sardar Further Details
646 GSK Factors influencing immune response and patient outcomes following influenza vaccination. Health Protection Research Group, University of Nottingham Dr Subhadra Rajanaidu Further Details
647 GSK Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials Institute for Clinical Research and Health Policy Studies, Tufts Medical Center David M. Kent, MD, MSc Further Details
651 GSK Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children. P95 Pharmacovigilance and Epidemiology Services Thomas Verstraeten Further Details
653 GSK Functional Estimation of Interventional Effects Department of Economics, Indiana University, Bloomington, Professor Sungkyunkwan University, Professor of Economics Joon Park Further Details
654 GSK, ViiV Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7) Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany Ulrich Jaehde Further Details
657 GSK Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials McMaster University Holger Schunemann, MD, MSc, PhD Further Details
668 GSK Associations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertension Flinders University, School of Medicine, Adelaide, Australia; Southern Adelaide Health Network, Adelaide, Australia Arduino A Mangoni Further Details
669 GSK A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes. University of Adelaide Jon Jureidini Further Details
672 GSK The Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with Lapatinib Memorial Sloan-Kettering Cancer Center Dr. Mario Lacouture Further Details
674 GSK Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews andnetwork meta-analysis University of Liverpool Antony Marson Further Details
675 Novartis Validation study on magnitude of tumorshrinkage as a prognostic marker Medical School Hannover Hematologgy, hemostasis, oncology and stemcelltransplantation Carl-Neuberg-Str. 1 30627 Hannover, Germany Viktor Grünwald Further Details
679 GSK An Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to Montelukast University of North Carolina at Chapel Hill Division of Pulmonary and Critical Care Medicine 130 Mason Farm Rd Chapel Hill NC 27599-7020 Wayne H Anderson Further Details
681 GSK A randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patients Massachusetts General Hospital Alexa B. Kimball Further Details
911 GSK Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data Cedars-Sinai Medical Center Lindsy Forbess, MD, MSc Further Details
918 GSK Outcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary Syndrome New York Medical College, New York, NY. Partha Sardar MD Further Details
928 GSK Lung function and airway inflammation response after ozone exposure 0.25ppm UNC Hospitals Krista Todoric, MD Further Details
930 GSK MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies NIHR Exeter Clinical Research Facility University of Exeter Medical School Barrack Road Exeter EX2 5DW Professor Andrew Hattersley, M.D. FRS Further Details
945 ViiV THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS University Hospital Ramón y CAjal Santiago Moreno Further Details
946 GSK Assessing models for changes in tumour size over time and how they relate to survival times. Division of Mathematics, University of Dundee, Dundee, UK. Raluca Eftimie Further Details
951 GSK Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia The University of Jordan Mohammad Saleh Further Details
955 GSK A study of subgroup identification and micro aggregation National Institute of Statistical Sciences www.niss.org S. Stanley Young Further Details
956 Roche Bone Quality Project University of California, San Francisco Dennis M. Black Further Details
976 GSK 5-alpha reductase inhibitor use and risk of lung cancer Department of Internal Medicine University of Manitoba Department of Medical Oncology and Hematology Cancercare Manitoba Marshall Pitz Further Details
977 GSK The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation University of Zurich Institute of Social and Preventive Medicine Hirschengraben 84 CH-8001 Zurich Milo Puhan Further Details
980 GSK Association of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patients Institute of Epidemiology and Preventive Medicine, National Taiwan University. Department of Family Medicine, Renai Branch, Taipei City Hospital Yi-Fan Wu Further Details
982 ViiV Pharmacokinetic modeling of dolutegravir in HIV patients. National Brain Research Centre,Manesar,Haryana,Gurgaon,India-122050 V P Subramanyam Rallabandi Further Details
988 Roche PhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical Data School of Health and Related Research (ScHARR) at the University of Sheffield Fabrizio Messina Further Details
989 GSK Assessing at the participant level the applicability of clinical trials to a specific patient Lister Hill National Center for Biomedical Communications, US National Library of Medicine, NIH Amos Cahan Further Details
993 GSK A Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD. Yale University School of Medicine Carlos A. Vaz Fragoso, MD Further Details
995 Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCB Identifying immune modulating patterns across diseases from open clinical trial data Institute for Computational Health Sciences UCSF School of Medicine Mission Hall - 550 16th St, San Francisco, CA 94158 email:Atul.Butte@ucsf.edu Phone: 415-514-0511 Further Details
997 GSK Predictors of Prostate Cancer Progression Among Men on Active Surveillance Duke University Stephen Freedland, MD Further Details
998 GSK Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus Rush University Medical Center Meenakshi Jolly, MD, MSCP Further Details
999 Boehringer Ingelheim, GSK Assessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized Trials Thomson Reuters Kristen M Sweet Further Details
1000 GSK Review of fever and febrile convulsion rates in children after trivalent influenza vaccine. National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead Dr Jean Li-Kim-Moy, MBBS, FRACP Further Details
1002 GSK Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease Kansas City University of Medicine & Biosciences Michael Sarai Further Details
1013 GSK Biopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized Medicine Princess Margaret Cancer Centre, University Health Network, Surgical Oncology, Urologist. Girish Kilkarni, MD, PhD Further Details
1015 GSK Pazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric study Department of Medical Oncology University Campus Bio-Medico Via A. Del Portillo 200, 00128 Rome, Italy Bruno Vincenzi, MD, PhD Further Details
1016 GSK Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique. London School of Hygiene and Tropical Medicine Paul Milligan Further Details
1020 GSK Genomic prediction tools developed using phenotypes from disease progression models University of Chicago Manish Sharma, MD Further Details
1022 Novartis Prediction of maximal work load (Wmax)in a bicycle test in patients with COPD. Dept of Respiratory Medicine & Allergology Lund University Hospital 22185 Lund, Sweden Göran Eriksson Further Details
1028 ViiV Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN José Ramón Blanco Further Details
1053 GSK Validation of the spirometric LMS equations in the Spanish population Respiratory department, Universitary Hospital of Araba Dr. Patricia Sobradillo Further Details
1057 GSK Health-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanib Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University Chang Wook Jeong Further Details
1058 ViiV Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data me Centre for Health & Infectious Diseases Research Rigshospitalet, University of Copenhagen CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret Blegdamsvej 9 DK-2100 Copenhagen Ø Denmark Alvaro H Borges Further Details
1071 Boehringer Ingelheim, GSK Optimising the Analysis of vascular Prevention trials (OA-Prevention) University of Nottingham Further Details
1073 GSK End-of-life trajectories in COPD CIRO+, centre of expertise for chronic organ failure; Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands Dr. Daisy J.A. Janssen Further Details
1075 Roche Efficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical Trials Department of Biostatistics & Bioinformatics Duke University Xiaofei Wang Further Details
1078 Lilly Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials University Hospital Geelong, Australia Seetal Dodd Further Details
1079 ViiV The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals. Deparment of Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spaon. Sergio Serrano-Villar, MD PhD Further Details
1084 GSK Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials. Karolinska Institutet Department of Medicine Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), D1:00, Karolinska University Hospital, Stockholm, Sweden Ronald van Vollenhoven, MD, PhD Further Details
1085 Roche Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B The University of Jordan Mohammad I Saleh, PhD Further Details
1086 ViiV Abacavir HLA-B*57:01 tolerance and genetic variation within the MHC. Institute for Immunology & Infectious Diseases, Discovery Way, Murdoch, WA 6150 Elizabeth Phillips, MD Further Details
1088 GSK A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants. University of North Carolina at Chapel Hill Joann Gruber Further Details
1090 GSK Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037) Fred Hutchinson Cancer Research Center; Department of Biostatistics, University of Washington M. Elizabeth Halloran Further Details
1100 Boehringer Ingelheim Systolic blood pressure level and risk of intracerebral hemorrhage. Julius Center for Health Sciences and Primary Care UMC Utrecht Jacoba P Greving Further Details
1103 GSK A study on the possible association between antidepressant response to SSRIs and proneness for side effects Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden Elias Eriksson, MD, PhD Further Details
1108 GSK Correlation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis. Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland Chaigne Benjamin Further Details
1125 Lilly Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. Department of Psychiatry and Psychotherapy TU-München Stefan Leucht Further Details
1128 GSK EuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinoma Leiden University Medical Center (LUMC) Prof. H.J. Guchelaar Further Details
1130 GSK, UCB Factors that determine placebo response in epilepsy trials Center for Biostatistics Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai One Gustave Levy Place, Box 1077 New York, NY 10029 Emilia Bagiella Further Details
1132 GSK Cytokine patterns in anti-viral disease vaccines: a knowledge driven approach Division of Systems Medicine Chief Department of Pediatrics Stanford University Atul J. Butte, MD, PhD Further Details
1134 GSK Incidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studies AO FBF e Oftalmico, Milano Italy Prof. Savino Bruno, MD Further Details
1136 Takeda Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab? University of Michigan Peter Higgins Further Details
1137 GSK Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Imperial College London Roy Anderson, PhD Further Details
1140 Boehringer Ingelheim Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib MD Anderson Cancer Center John Heymach, MD, PhD Further Details
1141 GSK Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes Nuffield Department of Primary Care Health Sciences, University of Oxford Merryn Voysey Further Details
1142 Boehringer Ingelheim, GSK, UCB A meta-analysis of Parkinson’s disease Division of Systems Medicine Department of Pediatrics Stanford University Atul Butte Further Details
1148 Lilly Meta-analysis of the risk of relapse in bipolar disorder FIDMAG Germanes Hospitalàries & King’s College London Dr. Joaquim Radua Further Details
1152 Boehringer Ingelheim Advanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trial Yale School of Medicine Center for Outcomes Research and Evaluation Nihar Desai, MD, MPH Further Details
1154 GSK Developing New Outcome Measures for SLE by Deconvoluting Available Datasets Lupus Research Institute Peter E. Lipsky, MD Further Details
1157 GSK Quality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial) Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University Chang Wook Jeong Further Details
1159 ViiV Validation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa Dataset University of Alabama at Birmingham Edward P. Acosta, Pharm.D. Further Details
1160 Boehringer Ingelheim Development of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulation Department of Epidemiology and Biostatistics College of Public Health University of Georgia Athens, GA 30602 Mark H. Ebell MD, MS Further Details
1161 Roche Novel approaches to the prediction of influenza complications Department of Epidemiology and Biostatistics College of Public Health University of Georgia Athens, GA 30602 Mark H. Ebell Further Details
1173 GSK, Lilly Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis Interdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the Netherlands Ymkje Anna de Vries Further Details
1180 GSK Evaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures. Department of Internal Medicine, University of Genoa, Genoa, Italy. Edoardo G. Giannini Further Details
1186 GSK Using generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinoma IDDI inc Marc Buyse Further Details
1206 GSK Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL) Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, Germany Kuhn, Annegret Further Details
1224 GSK INTERACTION BETWEEN MENINGOCOCCAL SEROGROUP B VACCINE (BEXSERO™) AND ROUTINE INFANT VACCINES ON THE RISK OF OCCURRENCE AND RECURRENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION. Institut National de Santé Publique du Québec(INSPQ) and Laval University Gaston De Serres Further Details
1234 Lilly Predictors of Placebo Response in Pediatric Patients with Generalized Anxiety Disorder University of Cincinnati Jeffrey R. Strawn Further Details
1236 GSK COPERNICUS re-analysis Magdi Yacoub Institute - Heart Science Centre National Heart & Lung Institute (Myocardial Function Section) Harefield Hospital Hill End Road Harefield, Middlesex, UB9 6JH John Cleland Further Details
1250 Boehringer Ingelheim, Lilly The relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patients Department of Psychiatry II, Ulm University Markus Koesters Further Details
1256 GSK Population mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patients Head of Department, Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine research Unit (MORU) Joel Tarning Further Details
1257 GSK An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data Yale University School of Medicine Yale-New Haven Hospital Center for Outcomes Research and Evaluation Joseph S. Ross, MD, MHS Further Details
1258 Roche Advance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation study University of Texas, Houston, Texas, USA Syed Hasan Raza Jafri Further Details
1273 GSK Post-hoc analysis of placebo-controlled trials in children and adolescents with depression University of Gothenburg Elias Eriksson Further Details
1277 Roche Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Imperial College London Roy Anderson Further Details
1280 GSK Placebo and nocebo effects in migraine Ver 2 University Hospitals Tuebingen Dept. of Internal Medicine Tuebingen, Germany Paul Enck Further Details
1292 Lilly Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity University of California, Los Angeles Alex Sturm Further Details
1293 Roche INCIDENCE OF BRAIN METASTASES IN METASTATIC BREAST CANCER PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: A METAANYLSIS OF FIVE PROSPECTIVE RANDOMIZED PHASE III TRIALS Medical University of Vienna, Comprehensive Cancer Center Vienna Rupert Bartsch Further Details
1295 Boehringer Ingelheim A Swapping Method Based on Covariate Classification for Average TreatmentEffect Estimation. University of Maryland, Baltimore County (UMBC), Department of Mathematics and statistics Dr. Bimal Sinha Further Details
1307 Takeda The Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease Seven Oaks General Hospital Renal Program Dr. Navdeep Tangri Further Details
1316 Boehringer Ingelheim Blinding (Masking) and the Placebo Effect University of Michigan Medical School James Brian Byrd, MD, MS, FAHA, FACC Further Details
1320 GSK Utility of a measure of Lupus Low Disease Activity State in SLE Monash Health Pei Xuan Ong (Emily) Further Details
1321 GSK Bone Quality Project University of California, San Francisco Dennis M. Black Further Details
1322 GSK Comparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level data None Giulio Pareto Further Details
1323 Lilly Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques KKT Technology pte. ltd. Praveen Deorani Further Details
1326 Lilly Reliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, Revised SUNY Upstate Medical University Steven V. Faraone, Ph.D. Further Details
1331 Boehringer Ingelheim Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke Medical University of South Carolina in Public Health Sciences Colleen Bauza Further Details
1335 GSK, UCB Investigation into the natural course of epilepsy and the implications on clinical trials NINDS, National Institutes of Health Daniel Goldenholz Further Details
1341 Boehringer Ingelheim Vol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial Results Dana-Farber Cancer Institute Harvard Medical School Geoffrey R. Oxnard Further Details
1343 GSK Improving the Assessment of Systemic Lupus Erythematosus Disease Activity University of Toronto, University Health Network Zahi Touma Further Details
1373 GSK An exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorder University of Kentucky Jonathan H. Smith, M.D. Further Details
1374 GSK A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy University of Pittsburgh Michael M. Wagner Further Details
1377 GSK The association between patient outcomes under two treatments (ABOUT) in cross-over trials IDDI 30 avenue provinciale 1340 Louvain-la-Neuve Belgium Marc Buyse, ScD Further Details
1387 GSK Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children Nuffield Department of Primary Care Health Sciences, University of Oxford Merryn Voysey Further Details
1393 Roche Prognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT study Department of Internal Medicine, Seoul National University Hospital Sae-Won Han Further Details
1401 Sanofi Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials McMaster University Holger Schunemann Further Details
1403 ViiV Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM Hospital General Universitario Gregorio Marañón Juan Berenguer Further Details
1421 GSK Cost utility analysis comparing belimumab against rituximab in systemic lupus erythematosus Wingate University Chris Gillette Further Details
1422 UCB Developing new outcome measures for SLE by deconvoluting available data sets LRI Peter E. Lipsky, MD Further Details
1428 Boehringer Ingelheim Estimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation. University Medical Center Utrecht, Utrecht, the Netherlands Frank L.J. Visseren Further Details
1430 GSK Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials. Department of Medicine, Solna Ronald van Vollenhoven Further Details
1433 Boehringer Ingelheim, Lilly, Roche Identification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times. INSERM U1153 METHODS team, Paris, France Ludovic Trinquart Further Details
1450 Boehringer Ingelheim, Novartis Understanding effectiveness of new drugs in older adults shortly after market entry. Brigham and Women's Hospital and Harvard Medical School Shirley V Wang Further Details
1451 GSK Assessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trial McGill University Samy Suissa Further Details
1452 GSK A study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countries University of North Carolina at Chapel Hill Sylvia Becker-Dreps Further Details
1455 Boehringer Ingelheim Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands Jacoba Greving Further Details
1456 ViiV Impact of ongoing side effects on the efficacy of initial antiretroviral therapy St Vincent's Hospital, Sydney Andrew Carr Further Details
1457 Lilly Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. Department of Psychiatry and Psychotherapy TU-München Stefan Leucht Further Details
1461 Lilly Regression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alpha Boston University Allan J. Walkey Further Details
1470 Takeda, UCB The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease Gastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China Director, IBD Service, Sheba Medical Center, Tel-Aviv University, Israel Shomron Ben-Horin M.D. Further Details
1473 Roche Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies (1) Department of Laboratory Medicine, National Taiwan University Hospital (2) Institute of Epidemiology and Preventive Medicine, National Taiwan University Keh-Sung Tsai Further Details
1475 Boehringer Ingelheim Predicting safety and efficacy of afatinib treatment of NSCLC Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia Assoc/Prof Michael Sorich Further Details
1481 GSK Efficacy and safety of belimumab in childhood-onset lupus Columbia University Medical Center 630 168th St, Room PH 10-08 New York NY 10032 Dr Anca Askanase MD, MPH Further Details
1514 Roche Gain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatment Department of Ophthalmology, Seoul National University Bundang Hospital Park, Sang Jun Further Details
1526 GSK Assessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes. Department of Management London School of Economics Houghton Street London WC2A 2AE Lawrence D Phillips Further Details
1528 GSK A Swapping Method for Average Treatment Effect Estimation Statistics, the University of Maryland at Baltimore County (UMBC) Bimal Sinha Further Details
1540 GSK IMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice. Brown University Dr. Issa Dahabreh Further Details
1541 Roche Item calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures. Wilmer Eye Institute Johns Hopkins School of Medicine Judith E. Goldstein Further Details
1542 Boehringer Ingelheim Optimising the Analysis of vascular Prevention trials (OA-Prevention) University of Nottingham Philip Bath Further Details
1558 GSK, Novartis Development of historical control using placebo data from pediatric epilepsy studies UCB BioSciences, Inc 8010 Arco Corporate Drive Suite 175 Raleigh NC 27613 Anthony Daniels Further Details
1566 Lilly A microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placebo University of Utah School of Medicine Department of Psychiatry & Psychiatric & Behavioral Solutions LLC Frederick W. Reimherr MD Further Details
1567 Boehringer Ingelheim, Takeda Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes University of Exeter Medical Scool (Honorary Consultant Physician (Diabetes) Royal Devon and Exeter Hospital) Andrew Hattersley Further Details
1569 GSK Melancholic symptoms in bipolar depression and response to lamotrigine Department of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, Canada Dr. Evyn Peters Further Details
1572 Boehringer Ingelheim, Eisai, GSK, Lilly Research to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs) Department of Breast and Medical Oncology National Cancer Center Hospital, National Cancer Center, Japan Kan Yonemori, MD., PhD Further Details
1575 GSK, Lilly Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder Interdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the Netherlands Ymkje Anna de Vries Further Details
1581 GSK MASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapy University of Bath Professor Chris Jennison Further Details
1587 Astellas Sex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analyses dept. of general practice, University Medical Center Groningen, University of Groningen, the Netherlands Marco H. Blanker, MD PhD Further Details
1593 GSK JANUVIA/JANUMET HTA Submission(Germany) MSD Sharp & Dohme GmbH Dr. Rainer Woker Further Details
1595 Boehringer Ingelheim, GSK, Lilly, Roche A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials Cytel Statistical Software and Services Pvt. Ltd Sharayu Paranjpe Further Details
1599 Roche Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma. Flinders University Michael Sorich Further Details
1600 Lilly Item factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimates University of California, Los Angeles Alexandra Sturm, Ph.D. Further Details
1601 Sanofi Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trials Chief of Surgery, JCHO Nihonmatsu Hospital Research Professor, Fukushima Medical University Akira Tsuburaya, MD PhD Further Details
1619 Boehringer Ingelheim Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical models EBSCO Information Services Brian S. Alper, MD, MSPH, FAAFP Further Details
1622 ViiV A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies School of Population and Public Health Steve Kanters Further Details
1624 Lilly A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs). The Zucker Hillside Hospital Christoph U Correll Further Details
1626 GSK Factors associated with Prostate Cancer in Prostate Needle Biopsy University of Illinois at Chicago Daniel M. Moreira Further Details
1629 GSK Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children University of Oxford Merryn Voysey Further Details
1630 GSK A framework for individualized prediction of the rate and severity of asthma exacerbations Faculty of Pharmaceutical Sciences and Faculty of Medicine, University of British Columbia Mohsen Sadatsafavi Further Details
1633 ViiV Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study. Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN Jose Ramon Blanco Further Details
1637 Novartis 1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World Benchmarks University at Buffalo, SUNY Dr. Jeffrey Lackner Further Details
1640 GSK Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial Lewis Katz School of Medicine, Temple University. Victor Kim Further Details
1643 Astellas, Lilly, Novartis, Roche Development of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trials The Institute of Statistical Mathematics, Research Organization of Information and Systems, Tokyo, Japan Hisashi Noma Further Details
1646 Lilly Effects of tumor burden change (response) on survival in mesothelioma Mayo Clinic Aaron Mansfield Further Details
1654 GSK, Lilly Placebo Response in Major Depressive Disorder. University of California, Los Angeles Ariana Anderson Further Details
1660 Sanofi Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare University of North Carolina at Chapel Hill, Department of Epidemiology, Gillings School of Global Public Health Jennifer L. Lund Further Details
1668 Roche Quantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016) Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital Pei Hu Further Details
1675 Lilly Efficacy and tolerability of SNRIs in depression. Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden Elias Eriksson Further Details
1684 Roche ANSELMA Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysis Gustave Roussy BENJAMIN BESSE Further Details
1688 Novartis Translational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression. National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Denis Collins Further Details
1691 GSK Longitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76 Pfizer Austin Huang Further Details
1692 Boehringer Ingelheim, GSK Predictors of chronic obstructive pulmonary disease progression Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, Japan Akihiro Hisaka Further Details
1693 Lilly, Novartis Identifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level Data University of Manchester Nophar Geifman Further Details
1695 GSK Outcome measures and baseline predictors of response to belimumab treatment. Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Ioannis Parodis Further Details
1702 Roche Pooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patients Institut Jules Bordet BrEAST Data Center, Brussels Belgium Evandro de Azambuja Further Details
1707 Lilly Comparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational Studies The University of Hong Kong Duke University (Adjunct) Herbert Pang Further Details
1721 Lilly, Roche Improving the evaluation of new cancer therapies to expedite patient access University of Adelaide Professor Jonathan Karnon Further Details
1726 Takeda, UCB Association Between Obesity and Response to Biologic Therapy in Inflammatory Bowel Diseases University of California San Diego Siddharth Singh Further Details
1731 GSK Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data Department of Epidemiology, Rollins School of Public Health, Emory University Julia M. Baker Further Details
1732 Astellas, Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. University of Glasgow Dr David A McAllister Further Details
1733 Roche Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment Rady Faculty of Health Sciences, University of Manitoba Children's Hospital Research Institute of Manitoba, University of Manitoba Lily Lim Further Details
1741 Lilly Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer. Flinders University Dr Ashley Mark Hopkins Further Details
1749 GSK, Novartis, Roche Bisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-Analyses Division of Nephrology, Department of Medicine, McMaster University, Department of Health Research Methods, Evidence and Impact, affiliated to Research St. Joseph's - Hamilton Dr. David Collister Further Details
1752 GSK Sex Differences in responses to umeclidinium-vilanterol treatment in COPD patients Istituto superiore di sanità, Italy Elisabetta Straface Further Details
1758 Novartis Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease Tufts Medical Center/Tufts Medical School Lesley A. Inker, MD Further Details
1764 Sanofi, Takeda Personalized Medicine Model Builder and Evaluation for Diabetes Treatments Queens College, CUNY and the Wharton Business School of the University of Pennsylvania Adam Kapelner Further Details
1779 GSK Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD Division of Infection, Immunity and Respiratory Medicine University of Manchester, UK Professor Jørgen Vestbo DMSc FRCP FERS Further Details
1786 Lilly, Novartis, UCB The efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials data University of Toronto, Women's College Hospital, Toronto, ON, Canada Dr Lihi Eder Further Details
1794 Roche A study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials. Centre for Investigational New Product, National Pharmaceutical Regulatory Agency (NPRA) Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia OH CHEN WEI Further Details
1808 Roche, UCB Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal. José A. P. da Silva Further Details
1813 Takeda, UCB Comparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysis Mayo Clinic Purna C. Kashyap, MBBS Further Details
1816 Lilly, Roche Individual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer: A meta-analysis by the GASTRIC group Gustave Roussy Cancer Center Biostatistics and epidemiology dpt INSERM CESP U1018 OncoStat Meta-analysis platform 114 rue Ed Vaillant 94805 Villejuif cedex, France Xavier Paoletti Further Details
1819 GSK INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF ANTIDEPRESSANT TRIALS FOR MAJOR DEPRESSION IN JAPAN Hiroshima University Shigeto Yamawaki Further Details
1831 GSK, Novartis, Takeda Statistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized Trials Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University Michael Rosenblum Further Details
1843 GSK The genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetes University of Dundee Dundee DD1 9SY Ewan Pearson Further Details
1844 GSK Real World Effects of Medications for Chronic Obstructive Pulmonary Disease London School of Hygiene & Tropical medicine (LSHTM) Dr Kevin Wing Further Details
1847 Sanofi Antiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy. University Paris-Sud and Gustave Roussy, Department of Medicine 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France Phone: +33 (0)1 42 11 43 22 Fax: +33 (0)1 42 11 52 19 Benjamin Besse Further Details
1851 Roche Validation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set. UCSD School of Medicine Kenneth Kalunian Further Details
1857 GSK, Novartis Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital Andrea C. Tricco Further Details
1880 Boehringer Ingelheim, Eisai, Lilly, Roche, Sanofi Improving the evaluation of new cancer therapies to expedite patient access University of Adelaide Professor Jonathan Karnon Further Details
1907 GSK Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS. European institute of Oncology , Milan Tommaso De Pas Further Details
1911 Boehringer Ingelheim, Daiichi Sankyo Lower incidence of atrial fibrillation in NOAC treated patients without prior AF Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands Ömer Erküner Further Details
1925 GSK EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysis University of Liverpool Catrin Tudur Smith Further Details
1928 GSK The development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1C The University of Jordan Mohammad Saleh Further Details
1933 Novartis Benefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harms University of Zurich Institute of Social and Preventive Medicine Hirschengraben 84 CH-8001 Zurich Alessandra Spanu Further Details
1934 GSK Using zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenza Genentech, Inc., A member of the Roche Group Lesley Butler Further Details
1955 Boehringer Ingelheim Development and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three months University Medical Center Utrecht, Utrecht, the Netherlands F.L.J. Visseren Further Details
1973 Roche The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute Elad Sharon Further Details
1996 Sanofi Statistical Methods for Causal Inference Adjusting for Adherence Southern Methodist University Department of Statistics University of Texas Southwestern Medical Center Department of Clinical Sciences Daniel Heitjan Further Details
2029 GSK Matching the Right Antidepressants with the Right Patients: Using Artificial Intelligence to Personalize the Treatment of Depression Douglas Mental Health University Institute McGill University Gustavo Turecki Further Details
2033 Boehringer Ingelheim Applying machine learning tools to personalize dabigatran treatment decisions Stanford University Sanjay Basu Further Details
2036 Boehringer Ingelheim Prediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED score Leiden University Medical Centre, Leiden, Netherlands Menno V Huisman Further Details
2056 Lilly Breakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis. The Zucker Hillside Hospital, The Feinstein Institute of Biomedical Research Northwell Health Jose M Rubio M.D. Further Details
2069 Lilly Estimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness. School of Health and Related Research (ScHARR), The University of Sheffield Ben Kearns Further Details
2074 Roche Association between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial Institut Jules Bordet Evandro de Azambuja Further Details
2084 GSK Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain Marc Miravitlles Further Details
2085 GSK Identify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial Analysis Johns Hopkins University Bloomberg School of Public Health Department of Health Policy and Management Center for Drug Safety and Effectiveness Center for Population Health IT Hongjun Kan Further Details
2087 Lilly Effectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revised Founder and Chief Scientific Officer, Ammonett Pharma Retired from University of Virginia after serving on faculty for 40 years as a clinical investigator, Division Chief Endocrinology and Metabolism, Chairman of the Department of Medicine Michael O. Thorner Further Details
2099 Boehringer Ingelheim Blood pressure variability in PRoFESS and development of incident stroke University of Utah, Department of Neurology Adam de Havenon Further Details
2100 GSK Review of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children. National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead Dr Jean Li-Kim-Moy Further Details
2110 Lilly Effects of tumor burden change (response) on survival in mesothelioma Mayo Clinic Aaron Mansfield Further Details
5453 Roche Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer American University of Beirut, Medical Center Youssef Zeidan Further Details
5459 GSK Placebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving Care The Ottawa Hospital Research Institute, University of Ottawa Shawn D. Aaron Further Details
5460 GSK The evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infections School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong. Prof Benjamin J Cowling Further Details
5471 GSK Evaluating predictors of antidepressant response or remission in children and adolescents with depression University of Maryland Baltimore, School of Pharmacy, Pharmaceutical Health Services Research Department O'Mareen Spence, MPH Further Details
5494 Sanofi Improving Colon Cancer Therapy Decisions by Extending Trial Representation Department of Epidemiology, University of North Carolina at Chapel Hill Jennifer Lund Further Details
5495 Boehringer Ingelheim Applying clinical trial results in clinical decision-making: Impact of a patien's baseline risk on the relative effect of an intervention strategy. University Medical Center Utrecht, Utrecht, the Netherlands Frank L.J. Visseren Further Details
5499 Roche Incorporating biomarkers into survival models to predict patient Rutgers University Dr. Luigi Brunetti, PharmD, MPH Further Details
5501 Roche Efficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer; A Combined Analysis Institut Jules Bordet Noam Pondé Further Details
5502 Lilly Health Determinants of the quality of life among children with ADHD: a structural equation modelling approach National Research Council, Neuroscience Institute, Padova, Italy Nadia Minicuci Further Details
5504 Boehringer Ingelheim Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic Methods University of North Carolina at Chapel Hill Michael Webster-Clark Further Details
5505 Boehringer Ingelheim, Lilly A Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive Symptoms Mayo Clinic, Dept. of Psychiatry and Psychology William V. Bobo Further Details
5506 Lilly Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed. Radboud University Medical Center Rob ter Heine Further Details
5509 Boehringer Ingelheim Statistical methodology for the analysis of incomplete data in non-inferiority clinical trials. University of Connecticut, Department of Statistics, CT, USA Yulia Sidi Further Details
5513 Lilly, Novartis Association of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach. Research Institute Brainclinics, Nijmegen, The Netherlands Utrecht University, Dept. of Experimental Psychology, Utrecht, The Netherlands Martijn Arns Further Details
5515 GSK Impact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategy National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences Fanghui Zhao Further Details
5521 GSK Impact of HPV vaccination in preventing subsequent infection and disease after excision treatment National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences Fanghui Zhao Further Details
5525 GSK Novel approaches for the analysis of SLE clinical trials Albert Einstein College of Medicine Mimi Kim Further Details
5528 Boehringer Ingelheim Spirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease Yale University School of Medicine Carlos A. Vaz Fragoso, MD Further Details
5548 Boehringer Ingelheim, Lilly, Roche Predictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer. Flinders University Ashley Hopkins Further Details
5549 Boehringer Ingelheim, GSK Model-based meta-analysis of anticoagulant therapy based on individual patient data Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan Hisaka Akihiro Further Details
5565 Eisai Predictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer. Flinders University Ashley Hopkins Further Details
5567 Lilly PROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome. University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OH Tithi Biswas Further Details
5602 Roche Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers. Flinders University Ashley Hopkins Further Details
5625 Roche Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response Stanford University Matthew Baker Further Details
5642 GSK FEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years. Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada Don D Sin Further Details
5644 GSK, Lilly, Sunovion Factor analysis using the Generalisability Theory of PANSS data from clinical trials in schizophrenia and bipolar disorder University Hospital Geelong, Barwon Health, Geelong, Australia Seetal Dodd Further Details
5652 UCB Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype University of California - San Francisco Vivek Rudrapatna Further Details
5655 Astellas, Bayer, Boehringer Ingelheim, GSK, Lilly, Roche, Sanofi, Takeda, ViiV Prediction of recruitment in randomized clinical trials (RECRUIT-IT) Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland Kasenda Benjamin Further Details
5658 GSK Does Shingrix vaccination reduces the risk of stroke? University of Antwerp & Antwerp University Hospital Benson Ogunjimi Further Details
5742 Boehringer Ingelheim, GSK, Novartis Comparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTs Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Head, the Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea Yeon-Mok Oh Further Details
5758 Roche Predicting the real world effectiveness and safety of medical interventions Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland Orestis Efthimiou Further Details
5769 GSK The risk of recurrent Plasmodium vivax malaria and haematological effect of treatment with or without primaquine: a systematic review and individual patient data meta-analysis Menzies School of Health Research, Darwin, Australia WorldWide Antimalarial Resistance Network (WWARN), University of Oxford, UK Rob Commons Further Details
5775 Roche Early identification of immunotherapy response based on computational models Applied Tumor Immunity (D120) National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ) Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany Gastroenterology and Gastrointestinal Oncology University Hospital RWTH Aachen Pauwelsstraße 30, D-52074 Aachen, Germany Jakob Nikolas Kather Further Details
5791 Novartis Trends of CRT therapy in heart failure patients with reduced ejection fraction on LCZ696 versus Enalapril University of Miami Abdullah Sarkar MD Further Details
5793 Astellas, UCB Predictors of exposure, therapeutic and adverse effects of certolizumab pegol used in the treatment of rheumatoid arthritis. Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia Ahmad Y Abuhelwa Further Details
5796 GSK, Lilly Symptom level analysis of recovery during antidepressant treatment Department of Psychology and Logopedics, Medical Faculty, University of Helsinki, Helsinki, Finland Markus Jokela Further Details
5805 GSK Choosing the Right Antidepressant for Depression: Individual Patient Data Network Meta-Analysis Department of Psychiatry, University of Oxford 	 Oxford Health NHS Foundation Trust Professor Andrea Cipriani Further Details
5806 GSK Melancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trials Department of Psychiatry, College of Medicine, University of Saskatchewan Dr. Evyn Peters Further Details
5807 Lilly, Novartis, Roche Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of breast cancer. Flinders University Ashley Hopkins Further Details
5808 Roche Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Leiden University Medical Center Diane van der Woude Further Details
5809 Roche Effectiveness of anti HER2 blockade according to host immune status Gangnam Severance Hospital Department of Surgery Joon Jeong Further Details
5814 UCB Calculating the Ankylosing Spondylitis Disease Activity Score (ASDAS) in radiographic and non-radiographic axial spondyloarthritis when Patient Global Assessment (PGA) is not available Leiden University Medical Center (LUMC) Désirée van der Heijde Further Details
5815 GSK Examining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trials Imperial College London Rachel Phillips Further Details
5819 GSK The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data University of Oxford Merryn Voysey Further Details
5835 GSK Combined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLE Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Savino Sciascia Further Details
5836 Roche Exploring possibilities to improve the risk:benefit balance through anlaysis of the ocrelizumab phase II extension study Blizard Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London 4 Newark Street London EC1 2AT David Baker/Klaus Schmierer Further Details
5847 GSK Effectivity of Belimumab in arthritic and hematologic SLE manifestations Dep. of Internal Medicine III Carl Gustav Carus Medical Center University of Dresden Germany Nicolai Leuchten Further Details
5851 Novartis Statistical Methods for Analyzing KCCQ in Heart Failure Trials Department of Mathematics & Statistics University of Maryland Baltimore County Baltimore, MD DoHwan Park, Ph.D. Further Details
5855 GSK A clinical practice for detecting the phases of Herpes Zoster. * Athens University of Economics and Business, Department of Statistics (www.stat-athens.aueb.gr ) * Frontier Science Foundation Hellas (www.frontier-science.gr ) Dimitris Karlis Further Details
5862 GSK Impact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus Erythematosus 1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece Katerina Chatzidionysiou Further Details
5865 GSK Hospitalized influenza clinical studies: benchmarking and refinement of clinical endpoints Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services (HHS) Kimberly Armstrong Further Details
5880 Roche Assessing immune system correlates to individual tumour size dynamics University of Manchester, Manchester, UK Dr Hitesh Mistry Further Details
5881 Novartis Relationship between outcomes and systolic blood pressure reduction during the first 24 h in acute heart failure syndrome: an exploratory analysis of the Relax-AHF-studies The University of Copenhagen, and the Department of Cardiology, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark Olav Wendelboe Nielsen Further Details
5886 GSK Efficacy of belimumab in patients with active systemic lupus erythematosus and concomitant antiphospholipid syndrome Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy. Pier Luigi Meroni Further Details
5895 ViiV Pharmacogenetics of Interaction between Efavirenz and Dolutegravir Vanderbilt University Medical Center Nashville, Tennessee David W. Haas, MD Further Details
5904 Lilly, Roche Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer Iowa State University Benjamin K Schneider Further Details
5906 UCB Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs University of Liverpool Laura Bonnett Further Details
5915 GSK SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical Immunology Savino Sciascia Further Details
5936 Takeda, UCB The impact of biological interventions on health-related quality of life in adults with Crohn's disease UHC rijeka, krešimirova 42, 51000 Rijeka, Croatia Mirjana Stanic Benic Further Details
5937 Roche Predictors of exposure, therapeutic and adverse effects of tocilizumab used in the treatment of rheumatoid arthritis. University of South Australia Ahmad Y Abuhelwa Further Details
5951 Lilly Alternative Data Presentation For Treatment Outcomes in Psoriasis University of Alberta, Faculty of Medicine & Dentistry, Division of Dermatology, Canada Robert Gniadeki Further Details
5979 Lilly Predictors of exposure, therapeutic and adverse effects of baricitinib used in the treatment of rheumatoid arthritis. Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia Ahmad Y Abuhelwa Further Details
5981 Roche Multi-state models for the analysis of survival data in radiation therapy. Department of Radiotherapy, Paoli Calmettes Institute, Marseille, France. Pierre Annede Further Details
5988 Lilly, Novartis, Roche Pattern Extraction and Patient-Level Prediction of Adverse Events Using Meta-Analysis and Matrix Decomposition Tokyo University of Science Kentaro Matsuura Further Details
5995 Novartis An investigation of clinical outcome measures in PPMS to inform the design of investigator initiated clinical trials. University of Calgary, Calgary, Alberta, Canada Marcus Koch MD PhD Further Details
6001 Lilly Can I use machine learning to build a prediction model of individual patient outcome in first episode psychosis? Institute of Mental Health & Wellbeing, University of Glasgow Honorary Specialty Registrar General Adult Psychiatry, NHS Greater Glasgow & Clyde Dr Samuel Leighton Further Details
6009 GSK Examining Immune Setpoints in Children and Adults Who Received Multivalent Hepatitis B Vaccines J. Craig Venter Institute (JCVI) Yun Zhang Further Details
6042 Astellas, Bayer, Eisai, GSK, Sanofi An investigation into unblinded sample size re-estimation methodology in clinical trials The University of Sheffield Julia Edwards Further Details
6066 Novartis Evaluating the role of Clinical Study Reports, as unpublished sources of evidence for the use of sacubitril/valsartan in adults and its impact on evidence synthesis. Department of General Practice and HRB Centre for Primary Care Research Dr David Byrne Further Details
6078 Novartis, Roche Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients American University of Beirut, Medical Center Youssef Zeidan Further Details
6080 Roche Exploratory Analysis of CRANE Influenza Study to Assess Impact of MHAA4549A among Subgroups Classified by Influenza Severity Veristat Robin Bliss Further Details
7082 Roche Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer. Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon. Youssef Zeidan Further Details
8102 GSK Open Label Extension Analysis - Exploring Self-Controlled Case Series Methodology London School of Hygiene and Tropical Medicine Ian Douglas Further Details
9115 GSK inhaled STerOids for the Prevention of Lung Cancer. (STOP Lung Cancer) Clínica Universidad de Navarra Luis Seijo Further Details
9131 GSK Validation of the diabetes microsimulation model in the HARMONY trial University of Florida College of Pharmacy Hui Shao Further Details
9134 ViiV Population pharmacokinetic analysis of interaction between dolutegravir and rifampin Department of Medicine University of Cape Town Health Sciences Faculty Gary Maartens Further Details
9140 Eisai INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF DONEPEZIL FOR ALZHEIMER'S DISEASE Kyoto University Graduate School of Medicine / School of Public health Toshi A. Furukawa Further Details
10189 Roche Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial American University of Beirut, Medical Center Youssef Zeidan Further Details
10195 GSK Relationship Between Baseline Blood Electrolyte Levels and Risk of Asthma Exacerbation Gossamer Bio Greg Opitek Further Details
11229 GSK Exploration of the Hospital Recovery Scale as an endpoint to assess clinical improvement in hospitalized influenza patients Janssen R&D Belgium Wilbert van Duijnhoven Further Details
11236 GSK Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) validation: post-hoc analysis of the BLISS-52 and BLISS-76 phase III trials. Professor of Rheumatology and Head of the CHUC Lupus Clinic, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra. Coimbra, Portugal Professor of Rheumatology at Faculty of Health Sciences, University of Beira Interior. Covilhã, Portugal Luís Inês Further Details
11254 GSK Evaluation of the pharmacokinetics of valacyclovir in subjects 1 month of age or older in order to assist in the design of a safer, more beneficial study of its pharmacokinetics in neonates under 2 weeks of age. University of Alabama at Birmingham David Kimberlin, MD Further Details
11283 GSK Association between Vaginal Infection and Cervical Non-HPV16/18 Infection in Women after Bivalent HPV Vaccination Cancer Hospital, Chinese Academy of Medical Sciences Fanghui Zhao Further Details
11298 GSK Development of personalised predictive models for the evolution of atopic dermatitis severity in response to treatment Department of Bioengineering, Imperial College London Reiko Tanaka Further Details
11302 GSK Assessment of the prognostic impact of including standard serological markers in the definitions of remission and low lupus disease activity in patients with SLE University of Crete Medical School; University Hospital of Heraklion, Greece George Bertsias Further Details
First 1 Last